SI2391352T1 - Farmacevtske oblike za sproščanje učinkovin - Google Patents
Farmacevtske oblike za sproščanje učinkovin Download PDFInfo
- Publication number
- SI2391352T1 SI2391352T1 SI201031619T SI201031619T SI2391352T1 SI 2391352 T1 SI2391352 T1 SI 2391352T1 SI 201031619 T SI201031619 T SI 201031619T SI 201031619 T SI201031619 T SI 201031619T SI 2391352 T1 SI2391352 T1 SI 2391352T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical
- ammonium
- formulation according
- pharmaceutical formulation
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
- Farmacevtske oblike za sproščanje učinkovin PATENTNI ZAHTEVKI1 .-Farmacevtska oblika, ki obsega glikozaminoglikan, izbran iz skupine, ki jo sestavljajo: bemiparin, fondaparinuks in enoksaparin in njegove farmacevtsko sprejemljive soli; in spojino, ki predstavlja neodvisne ali odvisne skupine pH kvaternarnih amonijevih skupin, ki je struktura polimerov in kopolimerov, dobljenih iz estrov akrilne in metakrilne kisline, kjer: - je delež amonijevih skupin v farmacevtski obliki med 0,01 in 2,0 pmol amonij/mg farmacevtske oblike, - delež glikozaminoglikana v farmacevtski obliki je med 15 % in 50 % w/w, in - v farmacevtski obliki je delež vlage (w/w) nižji od 10 %, pri čemer so polnitve glikozaminoglikana le delno nevtralizirane z izbranimi kationi, ki so odvisne ali neodvisne skupine pH kvartemih amonijevih vrednosti PH.
- 2.- Farmacevtska oblika v skladu z vsakim zahtevkom 1, kjer je spojina, odvisna ali neodvisna pH kvatemarna amonijeva skupina, ne-vodotopna spojina.
- 3 - Farmacevtska oblika v skladu z vsakim zahtevkom 1 do 2, kjer je delež amonijevih skupin v farmacevtski obliki med 0,05 in 1,7 pmol amonij/mg farmacevtske oblike.
- 4. -Farmacevtska oblika v skladu z zahtevkom 3, kjer je delež amonijevih skupin v farmacevtski obliki med 0,21 in 0,4 pmol amonijeve/mg farmacevtske oblike.
- 5. -Farmacevtska oblika v skladu z vsakim zahtevkom od 1 do 4, kjer je delež glikozaminoglikana v farmacevtski obliki med 25 in 50 % w/w.
- 6. -Farmacevtska oblika v skladu z zahtevkom 5, kjer je delež glikozaminoglikana v farmacevtski obliki med 33 in 50 % w/w.
- 7. -Farmacevtska oblika v skladu z vsemi zahtevki od 1 do 6, kjer ima farmacevtska oblika delež vlažnosti (w/w), nižji od 8 %.
- 8. -Farmacevtska oblika v skladu z vsakim zahtevkom od 1 do 2, kjer: - je delež amonijevih skupin v farmacevtski obliki med približno 0,16 in 1,7 pmol amonijevega/mg farmacevtskega sestavka in delež glikozaminoglikana v farmacevtskem sestavku med 20 % in 50 % w/w.
- 9. -Farmacevtska oblika skladno z vsakim zahtevkom 1 do 8, ki nadalje obsega farmacevtsko sprejemljive ekscipiente, kjer je odstotek (w/w) pomožnih snovi ali nosilcev v formulaciji enak ali nižji od 10 %.
- 10. -Farmacevtska formulacija, ki obsega farmacevtsko obliko, kot je opredeljena v zahtevku 9, kjer spojino, ki predstavlja kvatemame amonijeve skupine, tvori del površine omenjene formulacije.
- 11 .-Farmacevtska formulacija v skladu z vsakim zahtevkom od 9 do 10, kjer je omenjena formulacija pelet, granula, tableta ali mini tableta.
- 12. -Farmacevtska formulacija v skladu z vsakim zahtevkom od 9 do 11, kjer se omenjena formulacija uporablja oralno.
- 13. -Farmacevtska formulacija v skladu z zahtevkom 12, kjer je omenjena formulacija formulacija brez podaljšanega sproščanja.
- 14. -Farmacevtska oblika, kot je definirana v katerem koli izmed zahtevkov od 1 do 8, ali farmacevtska formulacija, kot je opredeljena v katerem koli od zahtevkov od 9 do 13, za uporabo kot zdravilo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382014A EP2213282A1 (en) | 2009-01-30 | 2009-01-30 | Pharmaceutical forms for the release of active compounds |
| PCT/EP2010/051127 WO2010086425A1 (en) | 2009-01-30 | 2010-01-29 | Pharmaceutical forms for the release of active compounds |
| EP10702287.3A EP2391352B1 (en) | 2009-01-30 | 2010-01-29 | Pharmaceutical forms for the release of active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2391352T1 true SI2391352T1 (sl) | 2018-04-30 |
Family
ID=40602343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201031619T SI2391352T1 (sl) | 2009-01-30 | 2010-01-29 | Farmacevtske oblike za sproščanje učinkovin |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP2213282A1 (sl) |
| CY (1) | CY1120050T1 (sl) |
| DK (1) | DK2391352T3 (sl) |
| ES (1) | ES2655689T3 (sl) |
| HR (1) | HRP20180103T1 (sl) |
| HU (1) | HUE037915T2 (sl) |
| LT (1) | LT2391352T (sl) |
| PL (1) | PL2391352T3 (sl) |
| PT (1) | PT2391352T (sl) |
| SI (1) | SI2391352T1 (sl) |
| WO (2) | WO2010086427A1 (sl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102120781B (zh) * | 2011-03-16 | 2013-07-17 | 中国药科大学 | 一种新型胰岛素口服纳米粒的制备及应用 |
| EP4287721A3 (en) | 2011-04-01 | 2024-02-21 | Mitsubishi Electric Corporation | User equipment performing radio communication and base station used in a communication system |
| EP3273239A1 (en) | 2016-07-19 | 2018-01-24 | Laboratorios Farmacéuticos Rovi, S.A. | Procedure of analysis of glycosaminoglycans, heparins and their derivatives by nuclear magnetic resonance |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3482014A (en) | 1966-06-29 | 1969-12-02 | Canada Packers Ltd | Orally active heparin and method for making and using same |
| US4703042A (en) | 1984-05-21 | 1987-10-27 | Bodor Nicholas S | Orally active heparin salts containing multivalent cationic units |
| US4925677A (en) * | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| FR2811227A1 (fr) * | 2000-07-07 | 2002-01-11 | Philippe Maincent | Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs |
| ITMI20012599A1 (it) | 2001-12-11 | 2003-06-11 | Cosmo Spa | Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int |
| US20050175693A1 (en) * | 2002-05-09 | 2005-08-11 | Peptron Co., Ltd | Substained release formulation of protein and preparation method thereof |
| GB0310919D0 (en) * | 2003-05-13 | 2003-06-18 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| ES2222822B1 (es) | 2003-07-28 | 2005-12-16 | Laboratorios Farmaceuticos Rovi, S.A. | Diamidas de aminoacidos en posicion no alfa utiles como adyuvantes para la administracion de agentes biologicos activos. |
| CN100534597C (zh) * | 2003-10-01 | 2009-09-02 | 德比欧药物研究有限公司 | 制备颗粒的装置及方法 |
| US7556826B2 (en) * | 2005-01-04 | 2009-07-07 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US20070154546A1 (en) | 2005-12-30 | 2007-07-05 | Zhang Jack Y | Sustained release pharmaceutical compositions |
| ES2296529B1 (es) | 2006-08-07 | 2009-04-01 | Laboratorios Farmaceuticos Rovi, S.A. | Composicion farmaceutica con promotores de absorcion. |
-
2009
- 2009-01-30 EP EP09382014A patent/EP2213282A1/en not_active Withdrawn
-
2010
- 2010-01-29 EP EP10702287.3A patent/EP2391352B1/en active Active
- 2010-01-29 WO PCT/EP2010/051129 patent/WO2010086427A1/en active Application Filing
- 2010-01-29 PL PL10702287T patent/PL2391352T3/pl unknown
- 2010-01-29 LT LTEP10702287.3T patent/LT2391352T/lt unknown
- 2010-01-29 PT PT107022873T patent/PT2391352T/pt unknown
- 2010-01-29 HU HUE10702287A patent/HUE037915T2/hu unknown
- 2010-01-29 ES ES10702287.3T patent/ES2655689T3/es active Active
- 2010-01-29 DK DK10702287.3T patent/DK2391352T3/da active
- 2010-01-29 SI SI201031619T patent/SI2391352T1/sl unknown
- 2010-01-29 WO PCT/EP2010/051127 patent/WO2010086425A1/en active Application Filing
-
2018
- 2018-01-16 CY CY20181100045T patent/CY1120050T1/el unknown
- 2018-01-19 HR HRP20180103TT patent/HRP20180103T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20180103T1 (hr) | 2018-04-20 |
| LT2391352T (lt) | 2018-05-25 |
| PT2391352T (pt) | 2018-01-19 |
| PL2391352T3 (pl) | 2018-05-30 |
| EP2391352B1 (en) | 2017-11-01 |
| DK2391352T3 (da) | 2018-01-29 |
| ES2655689T3 (es) | 2018-02-21 |
| WO2010086427A1 (en) | 2010-08-05 |
| EP2391352A1 (en) | 2011-12-07 |
| EP2213282A1 (en) | 2010-08-04 |
| HUE037915T2 (hu) | 2018-09-28 |
| CY1120050T1 (el) | 2018-12-12 |
| WO2010086425A1 (en) | 2010-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0514297A (pt) | composições farmacêuticas para liberação controlada de compostos biologicamente ativos | |
| RU2008136408A (ru) | Фармацевтическая композиция | |
| HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
| RU2641198C3 (ru) | Композиции glp-1 пептидов и их получение | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| BR112014009438A2 (pt) | composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral | |
| RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
| RU2019126797A (ru) | Составы твердых дозированных лекарственных форм антагониста орексинового рецептора | |
| UA93530C2 (ru) | Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения | |
| HRP20161340T1 (hr) | Formulacije darunavira | |
| HRP20151347T1 (hr) | Nova kombinacija | |
| SI2391352T1 (sl) | Farmacevtske oblike za sproščanje učinkovin | |
| HRP20180316T1 (hr) | Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala | |
| ATE542525T1 (de) | Verbesserte pharmazeutische zusammensetzung mit einem pyrrolidon-antikonvulsivum und verfahren zu seiner herstellung | |
| WO2011056785A3 (en) | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients | |
| WO2009084041A3 (en) | Pharmaceutical compositions of dexibuprofen | |
| EP2497464A3 (en) | Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture | |
| HRP20150387T1 (hr) | Sol kolina i trometamina od likofelona | |
| WO2008030512A3 (en) | Polystyrene sulfonate polymer tablets, their preparation and use | |
| SI2914599T1 (sl) | Oblika trdne soli kot alfa-6-mPEG6-O-hidroksikodon kot opioidni agonisti in uporabe le-te | |
| RU2017136567A (ru) | Фармацевтическая композиция с замедленным высвобождением, содержащая ривастигмин | |
| RU2015128915A (ru) | Составы лоразепама с замедленным высвобождением | |
| HRP20161153T1 (hr) | Farmaceutski pripravak koji sadrži aspirin i bisoprolol | |
| HRP20231252T1 (hr) | Farmaceutska kombinacija koja sadrži trazodon za liječenje neuropatske boli | |
| NZ710967A (en) | Pharmaceutical compositions containing dexketoprofen and tramadol |